Search

everythinglearnresearchcommunity

for

Search:↓

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

The post discusses a hair loss treatment routine involving dutasteride, topical finasteride, rosemary oil/onion juice/coffee solution, and stemoxydine. The user emphasizes the importance of consistency, realistic expectations, and a healthy lifestyle.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

The user experienced hair loss and itching after stopping RU58841 and resumed it to stop these symptoms. They also use Dutasteride and question which treatment is effective.

The user started finasteride again, using it every other day, along with a laser helmet, inversion massage, and various supplements. They are considering Minoxidil but had a bad reaction previously and plan to get hair grafts.

RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.

A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.

Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.

This post and conversation are about using receipt paper as a satirical treatment for hair loss. Users humorously discuss various absurd methods, including rubbing, ingesting, and making suppositories out of receipts.

A user shared their 14-month progress using finasteride, minoxidil, and dermarolling for hair loss, showing before and after pictures. Replies included brief comments and a question about the user's identity.

A user decided to stop using finasteride due to side effects and chose to shave their head instead. They plan to use the money saved for a hair transplant towards a house downpayment, hoping for future advancements in hair cloning.

A dermatologist advised stopping minoxidil and trying redensyl serum, while also starting finasteride. Concerns were raised about increased hair loss after stopping minoxidil.

The conversation is about personal experiences with Sonsuk Topical Finasteride, Minoxidil, and Tretinoin for hair loss. The original poster is seeking feedback after three weeks of use due to a lack of reviews.

The conversation humorously discusses hair loss treatments, including Minoxidil, finasteride, RU58841, and topical 17 alpha estradiol, with some users joking about transitioning to female to avoid baldness. The overall tone is satirical, emphasizing self-acceptance and the lengths people might consider for hair restoration.

The conversation discusses hair loss treatments, specifically Dutasteride, Minoxidil, RU58841, and derma pen use over six months. One user mentions RU58841 is effective but personally wouldn't use it.

The conversation is about hair loss treatments, specifically using dermarolling, rosemary oil, and minoxidil. The user experienced side effects with finasteride and is considering alternative treatments.

RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.

The conversation humorously discusses starting treatments like finasteride, dutasteride, RU58841, and oral minoxidil for hair loss. It highlights the challenges and experiences associated with these treatments.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

A college student is embarrassed after their roommate found and mocked their hair loss medications, including Minoxidil and finasteride. The student is advised to report the privacy violation and consider finding a new roommate.

The user has been using finasteride for 11 months, minoxidil for 3 months, and Serioxyl Advanced Denser Hair and alfatradiol pantostin for 1 month to address hair loss. Another user suggests switching from finasteride to dutasteride, but others argue finasteride is effective for the user.

A user has been using finasteride, minoxidil, RU58841, dutasteride, saw palmetto, and pumpkin seed oil but continues to experience significant hair shedding. They are seeking advice on what to do next.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.